Program
Fulvestrant
Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.
Drug pageFulvestrant: every studyMany companies study it; this page follows only the 25 they lead. All 122 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 211 open or running | phase 4since May 4, 2015 | Jul 21, 2003 | none ahead |
| Atossa Therapeuticsits history only | 10 open or running | phase 2since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Criteriumits history only | 11 open or running | phase 2since Sep 3, 2020 | Sep 3, 2020 | Dec 31, 2027phase 2 · NCT04567420 |
| Eagle Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 24, 2017 | Oct 24, 2017 | none ahead |
| Fresenius Kabiits history only | 10 open or running | phase 1since May 30, 2016 | May 30, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jul 21, 2003.
- Nov 20, 2005Phase 3 study in Breast NeoplasmsNCT00256698 · 514 enrolled · Canada, Costa Rica, Finland and more
- Nov 25, 2005Phase 2 study in Breast NeoplasmsNCT00259090 · 120 enrolled · United Kingdom
- Jan 4, 20063 phase 2 studiesNCT00272740, NCT00274469, NCT00278915
- Mar 20, 2006Phase 2 study in Breast NeoplasmsNCT00305448 · 143 enrolled · Japan
- Apr 10, 2006Phase 2 study in Breast NeoplasmsNCT00313170 · 144 enrolled · Belgium, Canada, Czechia and more
- May 18, 2006Phase 1 study in Advanced Breast CancerNCT00328120 · 20 enrolled · Japan
- May 18, 2006Phase 3 study in Advanced Breast CancerNCT00327769 · 234 enrolled · China
- Jun 5, 2006Phase 2 study in Endometrial NeoplasmsNCT00334295 · 35 enrolled · Germany
- Jul 20, 2006Phase 2 study in Breast NeoplasmsNCT00357110 · 13 enrolled · Austria, Germany, Norway
- Mar 7, 2008Phase 3 study in Advanced Breast CancerNCT00635713 · 588 enrolled
- Jul 22, 2009Phase 3 study in Breast NeoplasmsNCT00944918 · 25 enrolled · Korea, Republic of
- Feb 17, 2011Phase 3 study in Breast NeoplasmsNCT01300351 · 249 enrolled · China
- May 11, 2012Phase 3 study in NeoplasmsNCT01602380 · 462 enrolled · United States, Argentina, Brazil and more
- May 4, 2015Phase 4 study in Breast NeoplasmsNCT02447328 · 83 enrolled · Korea, Republic of
TargetBeta
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 21 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02447328Breast Neoplasms · Korea, Republic of | 4 | Completed | May 6, 2016 | 83 |
| NCT01602380Neoplasms · United States, Argentina, Brazil and more | 3 | Completed | Apr 11, 2016 | 462 |
| NCT01300351Breast Neoplasms · China | 3 | Completed | Mar 2014 | 249 |
| NCT00944918Breast Neoplasms · Korea, Republic of | 3 | Completed | Jun 2011 | 25 |
| NCT00635713Advanced Breast Cancer | 3 | Completed | 588 | |
| NCT00357110Breast Neoplasms · Austria, Germany, Norway | 2 | Completed | Oct 2008 | 13 |
| NCT00334295Endometrial Neoplasms · Germany | 2 | Completed | Jan 2011 | 35 |
| NCT00328120Advanced Breast Cancer · Japan | 1 | Completed | Apr 2006 | 20 |
| NCT00327769Advanced Breast Cancer · China | 3 | Completed | 234 | |
| NCT00313170Breast Neoplasms · Belgium, Canada, Czechia and more | 2 | Completed | Jun 13, 2008 | 144 |
| NCT00305448Breast Neoplasms · Japan | 2 | Completed | Mar 2008 | 143 |
| NCT00278915Puberty, Precocious · United States, France, Germany and more | 2 | Completed | Dec 8, 2009 | 30 |
| NCT00274469Breast Neoplasms · United States, Brazil, Bulgaria and more | 2 | Completed | Jan 10, 2008 | 205 |
| NCT00272740Breast Neoplasms · Belgium, Switzerland | 2 | Completed | 93 | |
| NCT00259090Breast Neoplasms · United Kingdom | 2 | Completed | Oct 2008 | 120 |
| NCT00256698Breast Neoplasms · Canada, Costa Rica, Finland and more | 3 | Completed | Apr 2009 | 514 |
| NCT00241449Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Mar 2007 | 51 |
| NCT00234403Breast Neoplasms · Spain | 2 | Completed | 60 | |
| NCT00099437Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Feb 27, 2009 | 736 |
| NCT00093002Breast Neoplasms · United States, Austria, Brazil and more | 2 | Completed | 179 | |
| NCT00065325Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Jun 2006 | 694 |
How it is read
Names in the registry
- “Fulvestrant”, 26 entries
- “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
- “fulvestrant”, 2 entries
- “faslodex 500mg”, 1 entry
- “Fulvestrant injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 23 studies
- Neoplasms, 1 study
- Carcinoma, Intraductal, Noninfiltrating, 1 study
- Puberty, Precocious, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.